Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...
A Teva Pharmaceuticals drug being developed in ... disease (IBD), results the companies say support the antibody’s best-in-class potential. The preliminary results announced Tuesday are from ...